Clinical Trial Update: A Study of Vismodegib in Patients With Relapsed/Refractory Acute Myelogenous Leukemia and Relapsed Refractory High-Risk Myelodysplastic Syndrome [Phase 2]

View source ↗

Summary

Phase 2 study of vismodegib in relapsed/refractory acute myeloid leukemia and relapsed/refractory high-risk myelodysplastic syndrome was terminated with results…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndromes

Drugs mentioned

• Vismodegib (Vismodegib)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Myelodysplastic Syndromes, Myelogenous Leukemia, Acute | Phase 2 | Status: TERMINATED | Results posted: 2015-12-15